Two years after publishing its first reversible terminator nucleotide, sequencing technology company LaserGen has developed a full set of reagents that it claims could improve a variety of existing and impending second-generation sequencing platforms.

The Houston-based startup plans to commercialize the reagents, called Lightning Terminators, for use with at least one existing sequencing platform. Long term, it wants to develop its own sequencing instrument.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Related Articles

Paired Ends: Jennifer Baldwin

Premium

Paired Ends: Jim Bristow

Premium

Paired Ends: Nick McCooke

Premium

Paired Ends: Chris Toumazou

Premium

Paired Ends: Edison Liu

Premium

Paired Ends: Sarah Cossey

Premium

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.